Anthony Mancini will help Genmab take its next steps

Last year, Anthony Mancini was hired by Genmab. Today, he plays a key role in a new chapter at the company, as Genmab begins to market and sell its own products within cancer treatment for the first time.

Photo: Genmab

Few firms have been progressing at the same speed as Genmab has the past few years.

The Danish biotech company, which is specialized in cancer treatment, has seen both its revenue and share price skyrocket year after year. Historically, the growth has been due to Darzalex, which is marketed by Johnson & Johnson, but today, Genmab has five drugs contributing to its revenue.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs